ADMA Biologics, Inc., a late-stage biopharmaceutical company developing specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, has entered into a loan and security agreement with Oxford Finance LLC for up to $21 million.

“This new funding from Oxford allows us to refinance our existing loan and provides us the opportunity to extend and increase our current cash resources, while further advancing our commercialization activities,” said Brian Lenz, vice president and chief financial officer, ADMA Biologics.

“Oxford is pleased to provide ADMA with capital as it works towards commercializing its lead product candidate, RI-002,” stated Christopher Herr, senior managing director, Oxford Finance. “After completing a robust due diligence process, we believe there is great potential for RI-002 in the marketplace.”